trial summary · NCT07645469
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia
Phase I Study of Autologous CD4+ and CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Treatment of MRD-Positive AML
Trial record from the TrialBase DB dataset, status RECRUITING, condition Acute Myeloid Leukemia, sponsored by Fred Hutchinson Cancer Center. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase I trial tests the safety, side effects and best dose of FH-WT1-E50 TCR T cells with azacitidine for the treatment of minimal residual disease (MRD) positive acute myeloid leukemia (AML). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize WT1, a protein on the surface of cancer cells. These WT1-specific T cells may help the body's immune system identify and kill WT1 cancer cells. Azacitidine is in a class of medications called antimetabolites. It works by stopping or slowing the growth of cancer cells. Giving FH-WT1-E50 TCR T Cells with azacitidine may be safe and/or effective for the treatment of MRD positive AML.
Source record: https://clinicaltrials.gov/study/NCT07645469
Facts
| registry id | NCT07645469 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Acute Myeloid Leukemia |
| sponsor | Fred Hutchinson Cancer Center |
| sponsor class | OTHER |
| enrollment | 9 |
| start date | 2026-12-01 |
| primary completion | 2030-07-19 |
| completion | 2030-07-19 |
| results posted | not reported |
Conditions
- Acute Myeloid Leukemia
Interventions
- Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells
- Azacitidine
- Biospecimen Collection
- Bone Marrow Aspiration
- Bone Marrow Biopsy
- Chest Radiography
- Computed Tomography
- Echocardiography Test
- Lumbar Puncture
- Multigated Acquisition Scan
- Positron Emission Tomography
Countries
- United States
Intervention types: DRUG, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.